BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 36408131)

  • 1. Identification and validation of a novel phagocytosis regulators-related signature with potential prognostic and immunotherapeutic value in patients with lung adenocarcinoma.
    Li J; Du Q; Sun J; Xiang L; Wang S
    Front Oncol; 2022; 12():988332. PubMed ID: 36408131
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Construction and Validation of Prognostic Risk Score Model of Autophagy Related Genes in Lung Adenocarcinoma].
    Zhou J; Wang X; Li Z; Jiang R
    Zhongguo Fei Ai Za Zhi; 2021 Aug; 24(8):557-566. PubMed ID: 34256900
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel pyroptosis-related prognostic signature for lung adenocarcinoma: Identification and multi-angle verification.
    Wang X; Zhou J; Li Z; Chen X; Wei Q; Chen K; Jiang R
    Front Genet; 2023; 14():1160915. PubMed ID: 37077542
    [No Abstract]   [Full Text] [Related]  

  • 4. A more novel and powerful prognostic gene signature of lung adenocarcinoma determined from the immune cell infiltration landscape.
    Ma C; Li F; He Z; Zhao S
    Front Surg; 2022; 9():1015263. PubMed ID: 36311939
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive analysis of a novel signature incorporating lipid metabolism and immune-related genes for assessing prognosis and immune landscape in lung adenocarcinoma.
    Wang Y; Xu J; Fang Y; Gu J; Zhao F; Tang Y; Xu R; Zhang B; Wu J; Fang Z; Li Y
    Front Immunol; 2022; 13():950001. PubMed ID: 36091041
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of a novel m5C/m6A-related gene signature for predicting prognosis and immunotherapy efficacy in lung adenocarcinoma.
    Ma Y; Yang J; Ji T; Wen F
    Front Genet; 2022; 13():990623. PubMed ID: 36246622
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integration of multiple key molecules in lung adenocarcinoma identifies prognostic and immunotherapeutic relevant gene signatures.
    Wu Q; Wang L; Wei H; Li B; Yang J; Wang Z; Xu J; Zhou YL; Zhang B
    Int Immunopharmacol; 2020 Jun; 83():106477. PubMed ID: 32278127
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel signature predicts prognosis and immunotherapy in lung adenocarcinoma based on cancer-associated fibroblasts.
    Ren Q; Zhang P; Lin H; Feng Y; Chi H; Zhang X; Xia Z; Cai H; Yu Y
    Front Immunol; 2023; 14():1201573. PubMed ID: 37325647
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development and validation of a robust immune-related prognostic signature in early-stage lung adenocarcinoma.
    Wu P; Zheng Y; Wang Y; Wang Y; Liang N
    J Transl Med; 2020 Oct; 18(1):380. PubMed ID: 33028329
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Establishment and validation of a prognostic signature for lung adenocarcinoma based on metabolism-related genes.
    Wang Z; Embaye KS; Yang Q; Qin L; Zhang C; Liu L; Zhan X; Zhang F; Wang X; Qin S
    Cancer Cell Int; 2021 Apr; 21(1):219. PubMed ID: 33858449
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel prognostic model related to oxidative stress for treatment prediction in lung adenocarcinoma.
    Peng H; Li X; Luan Y; Wang C; Wang W
    Front Oncol; 2023; 13():1078697. PubMed ID: 36798829
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Construction and analysis of a novel ferroptosis-related gene signature predicting prognosis in lung adenocarcinoma.
    Zhou J; Wang X; Li Z; Jiang R
    FEBS Open Bio; 2021 Nov; 11(11):3005-3018. PubMed ID: 34499810
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comprehensive Analysis of Immune Implication and Prognostic Value of
    Zeng Y; Zhang Z; Chen H; Fan J; Yuan W; Li J; Zhou S; Liu W
    Front Oncol; 2021; 11():798425. PubMed ID: 35047409
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor microenvironment related novel signature predict lung adenocarcinoma survival.
    Chen J; Zhou R
    PeerJ; 2021; 9():e10628. PubMed ID: 33520448
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of genes related to cancer-associated fibroblasts in lung adenocarcinoma.
    Peng J; He C; Yan H; Zhou W
    Technol Health Care; 2023; 31(6):2339-2354. PubMed ID: 37661904
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Construction and experimental validation of an acetylation-related gene signature to evaluate the recurrence and immunotherapeutic response in early-stage lung adenocarcinoma.
    Wang H; Lu X; Chen J
    BMC Med Genomics; 2022 Dec; 15(1):254. PubMed ID: 36503492
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development and validation of a prognostic risk signature for lung adenocarcinoma constructed by six ferroptosis, necroptosis, and pyroptosis-related lncRNAs.
    Peng L; Ji J; Zhang C; Wu Z; Sun Y; Fan K; Du W; Liu A; Jiao W
    J Thorac Dis; 2022 Oct; 14(10):3955-3974. PubMed ID: 36389299
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic characteristics of T-cell mediated cell killing-related genes in lung adenocarcinoma.
    Bi L; Ai C; Zhang H; Chen Z; Deng Y; Xiong J; Lv Z
    Autoimmunity; 2023 Dec; 56(1):2250097. PubMed ID: 37624966
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Construction of a Prognostic Immune-Related LncRNA Risk Model for Lung Adenocarcinoma.
    Li Y; Shen R; Wang A; Zhao J; Zhou J; Zhang W; Zhang R; Zhu J; Liu Z; Huang JA
    Front Cell Dev Biol; 2021; 9():648806. PubMed ID: 33869203
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of N7-methylguanosine related signature for prognosis and immunotherapy efficacy prediction in lung adenocarcinoma.
    Li Z; Wang W; Wu J; Ye X
    Front Med (Lausanne); 2022; 9():962972. PubMed ID: 36091687
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.